Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content

Middle East

EXCLUSIVE Teva Pharm unlikely to reach deals to co-produce vaccines -CEO

1 minute read

The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen

Israel’s Teva Pharmaceutical Industries (TEVA.TA) is not likely to reach deals with COVID vaccine makers to co-produce the vaccines although discussions are still ongoing, chief executive Kare Schultz told Reuters.

Schultz said Teva -- the world's largest generic drugmaker -- offered to co-produce the vaccines in both Israel and Europe, where the company has capacity, to help with global supply.

"But we've not been able to reach a firm agreement with any company," he said. "It's not for our lack of wanting to do it but the key players that have actually been successful in developing the vaccines that have come to the market have found other partners or their own internal capacity."

He did not name the companies.

"It's probably pretty much done (but) we can't rule it out," Schultz said. "We're still in discussion with some of the companies, and we're still willing to do it if we can help."

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters